Compare CCO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | XERS |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2005 | 2021 |
| Metric | CCO | XERS |
|---|---|---|
| Price | $2.33 | $8.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $2.12 | ★ $10.83 |
| AVG Volume (30 Days) | ★ 7.3M | 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.81 | 100.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,604,140,000.00 | $49,590,000.00 |
| Revenue This Year | $5.35 | $34.37 |
| Revenue Next Year | $4.26 | $22.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.57 | ★ 142.67 |
| 52 Week Low | $1.16 | $5.25 |
| 52 Week High | $2.44 | $10.08 |
| Indicator | CCO | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 32.05 | 57.24 |
| Support Level | $2.33 | $6.98 |
| Resistance Level | $2.41 | $9.01 |
| Average True Range (ATR) | 0.03 | 0.34 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 25.00 | 89.64 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.